Mike Hennessy Jr.

This issue of PharmTech brings together perspectives from scientists, engineers, regulatory strategists, and industry veterans to chart where the field is headed.

Today, we’re taking our brand to the next level so we can strengthen our commitment to scientists, innovators, and C-suite leaders who trust us for science-driven insights for faster and smarter manufacturing of safe, effective, successful therapies.

The articles in this issue reflect an industry in transition, committed to innovation while ensuring safe, reliable, and forward-looking pharmaceutical production.

Success depends on collaboration, resilience, and a focus on improving outcomes for patients worldwide.

This issue showcases strategies that organizations are adopting to stay competitive as pressing industry trends shape the sector.

Scientific discovery, technological evolution, and market demands are constantly reshaping the landscape.

Pharma manufacturing is headed toward smarter tools, deeper partnerships, and a renewed focus on compliance and quality at every stage of the product lifecycle.

Scientific breakthroughs, operational innovation, and cultural shifts are driving tomorrow’s medicines.

The pharma industry is focused on strengthening its foundation, embracing innovation, and future-proofing its path forward.

Over the course of the next five years, the bio/pharma industry is expected to see the patents of multiple blockbuster drugs expire, impacting some key industry players.

Artificial intelligence, among other technological advances, is pushing innovation boundaries.

If the conditions prove optimal, 2025 could be a prosperous year for bio/pharma business deals.

The 340B program is under greater scrutiny with more transparency for drug access being demanded by industry.

Recent hurricanes in the US close Baxter plant, shining a spotlight on supply chain fragility again.

How the Republican and Democrat presidential candidates might appeal to voters on this topic is starting to be seen.

A coordinated and international response is needed to help control the latest mpox outbreak in Africa.

Will Sanofi’s plan to recruit the younger generation through its participation in the upcoming 2024 Olympic and Paralympic Games, being held in Paris, pay off?

A greater number of patients with Duchenne muscular dystrophy will be able to be treated after FDA's approval of a gene therapy.

Improved efficiencies and reduced costs are clear advantages of automating drug manufacturing processes.

Technological advances are helping advance biologics development and manufacturing and reduce bottlenecks.

Experts believe it is likely cancer cells are more common in the body than previously thought, but typically caught early and removed in the body’s cancer-immune cycle. When the system is in good working order (and protecting us), dead cancer cells release neoantigens.

While Catalent’s acquisition is definitely about making drugs, it’s also very much about making money.

Given its positioning at each new year’s commencement, the J.P. Morgan Healthcare conference helps establish the tone with which the pharmaceutical industry is viewed.

GSI shortages result from how hospitals buy GSI drugs, and the underinvestment in manufacturing operations that follow.

Pharmaceuticals are entering a transition into a far more complex era of patient therapies, and patient segmentation.

Industry investments indicate increasing trust in the newest modalities, including mRNA approaches.

It has been a long wait, but for Alzheimer’s at least, this is the beginning of renewed hope.

Pharma's ability to continually reinvent itself will be critical in growing future business operations.